engleski

Low dose azithromycin vs high dose azithromycin in ranitidine bismuth citrate (RBC) based triple therapy for Helicoabcter pylori eradication

One-week triple therapies consisting of antisecretory agent plus two antibiotics have shown to be high effective in H. pylori eradication in controlled clinical trials. As the therapy consists of three different drugs, which should be taken at least twice daily, patient compliance plays an important role. Azithromycin’s pharmacokinetics properties offer possibility to make dosing regimen shorter and simpler. 149 H. pylori positive patients (detected by CLOtest, confirmed by histopathology and 13C-UBT) with endoscopically diagnosed duodenal/gastric ulcer, were randomly treated with either RBC 400 mg bid for 7 days, amoxicillin 1 g bid for 7 days and azithromycin 1 g od for 7 days (group A), or with RBC 400 mg bid for 7 days, amoxicillin 1 g bid for 7 days and azithromycin 1 g od for 3 days (group B). Assessment of H. pylori status and ulcer healing was performed 4 weeks after completion of therapy. H. pylori eradication (all tests negative) was achieved in 72/77 (93.5%) patients in group A, and in 62/72 (86.1%) in group B. Ulcers were healed in 74/77 (96.1%) and 69/72 (95.8%), respectively. Mild gastrointestinal side effects were recorded in 8 patients in group A and in 2 patients in group B. Conclusion: there is no statistically significant difference (p>0.05) in H. pylori eradication rate with azithromycin applied 1 g od for 3 days or for 7 days (86.1%, and 93.5%, respectively).

Helicobacter pylori; therapy; ranitidine bismuth citrate; RBC; azithromycin

nije evidentirano